At the time of writing, Maze Therapeutics Inc [MAZE] stock is trading at $41.39, up 2.99%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MAZE shares have gain 7.87% over the last week, with a monthly amount glided 4.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Maze Therapeutics Inc [NASDAQ: MAZE] stock has seen the most recent analyst activity on December 04, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $55. On September 02, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $30 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $34 on July 23, 2025. Wedbush initiated its recommendation with an Outperform and recommended $17 as its price target on July 08, 2025.
For the past year, the stock price of Maze Therapeutics Inc fluctuated between $6.71 and $43.29. Currently, Wall Street analysts expect the stock to reach $47.8 within the next 12 months. Maze Therapeutics Inc [NASDAQ: MAZE] shares were valued at $41.39 at the most recent close of the market. An investor can expect a potential return of 15.49% based on the average MAZE price forecast.
Analyzing the MAZE fundamentals
According to Maze Therapeutics Inc [NASDAQ:MAZE], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.45 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Maze Therapeutics Inc [NASDAQ:MAZE] has a current ratio of 17.70. As well, the Quick Ratio is 17.70, while the Cash Ratio is 14.33.
Transactions by insiders
Recent insider trading involved Bernstein Harold, President, R&D & CMO, that happened on Jan 07 ’26 when 25156.0 shares were sold. Director, Sohn Catherine A. completed a deal on Jan 07 ’26 to sell 26920.0 shares. Meanwhile, Director Sohn Catherine A. sold 2493.0 shares on Jan 06 ’26.
